维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

9篇 您的检索式：作者名="Alaimo D"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Role of calcium in E-selectin induced phenotype of T84 colon carcinoma cells显示文摘	D' Amato M Flugy AM Alaimo G	2003	Biochem Biophys Res Commun2003，301，4：	1
	2	Interplay of the Wzx translocase and the corresponding polymerase and chain length regulator proteins in the translocation and periplasmic assembly of lipopolysaccharide o antigen 显示文摘	Marolda C L Tatar L D Alaimo C	2006	J Bacteriol2006，188，14：	1
	3	Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo显示文摘	Wiessner C Sauer D Alaimo D	2000	Cell Mol Biol (Noisy-le-grand)2000，46，1：	1
	4	查看详情显示文摘	Rieger J Grazon C Charleux B Alaimo D JéRōMe C		0，，：	1
	5	Pegylat ed thermally responsive block copolymer micelles and nanogels viain situRAFT aqueous dispersion polymerization显示文摘	Rieger J Grazon C Charleux B Alaimo D Jerome C	2009	Journal o f Polymer Science Part a-Polymer Chemistry2009，47，：	1
	6	Inhibitory effects of glycoprotein II b/HI a antago- nists and aspirin on the release of soluble CD40 ligand during platelet stimulation显示文摘	NANNIZZI ALAIMO L ALVES V L PHIL1APS D R	2003	Circulation2003，107，：	1
	7	Amphiphilic poly (ethylene oxide) macromolecular RAFT agent as a stabilizer and control agent in ab initio batch emulsion polymerization显示文摘	Rieger J Stoffelbach F Bui C Alaimo D Jerome C Charleux B		0，，：	1
	8	Platelet-derived CD40L: the switch hitting player of cardiovascular disease显示文摘	ANDRE P NANNIZZI ALAIMO L Phillips D R	2002	Circulation2002，106，：	1
	9	Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy:A randomized controlled trial显示文摘AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in retreating chronic hepatitis C patients who relapsed after recombinant interferon (rIFN) monotherapy. METHODS: Forty-five patients (34 males and 11 females) with chronic hepatitis due to hepatitis C virus (HCV) genotype 1 who relapsed after a previous course of rIFN monotherapy were randomized to receive 9 μg CIFN three times per week for 52 wk (group A, n = 22) or 18 μg CIFN three times per week for 52 wk (group B, n = 23) in combination with ribavirin 800 to 1200 mg daily for 52 wk (according to body weight). Virological response was evaluated at week 24 (EVR), at the end of treatment (ETR) and at 76 wk (SVR). RESULTS: By intention-to-treat analysis, subjects in group A had an EVR in 35% of cases, an ETR in 35% and a SVR in 27.3% of cases. Subjects in group B had an EVR in 32% of cases, an ETR in 35% and a SVR in 26.1% of cases. Treatment was stopped because of adverse effects (mostly intolerance) in 15 patients (6 in group A and 9 in group B). IFN dose reduction was needed in 2 patients (1 in group A and 1 in group B). Ribavirin dose was reduced in 2 patients in group A and 1 in group B respectively. Among the 15 subjects who received at least 80% of the intended schedule, the rate of SVR was 80% (6 in group A and 6 in group B). CONCLUSION: CIFN in combination with ribavirin when given to HCV genotype 1 relapsers after rIFN monotherapy obtains an unsatisfactory rate of sustainedviral clearance independently of dosage of the drug. This may be due to its scarce tolerability.	Giuseppe Alaimo Vito Di Marco Donatella Ferraro Rosa Di Stefano Salvatore Porrovecchio Francesca D’Angelo Vincenza Calvaruso Antonio Craxì Piero Luigi Almasio	2006	World Journal of Gastroenterology2006，12，42：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费